Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
BMJ. 2011 Nov 18;343:d6891. doi: 10.1136/bmj.d6891.
To evaluate the association between non-alcoholic fatty liver disease and all cause and cause specific mortality in a representative sample of the US general population.
Prospective cohort study.
US Third National Health and Nutrition Examination Survey (NHANES III: 1988-94) with follow-up of mortality to 2006.
11,371 adults aged 20-74 participating in the Third National Health and Nutrition Examination Survey, with assessment of hepatic steatosis.
Mortality from all causes, cardiovascular disease, cancer, and liver disease (up to 18 years of follow-up).
The prevalence of non-alcoholic fatty liver disease with and without increased levels of liver enzymes in the population was 3.1% and 16.4%, respectively. Compared with participants without steatosis, those with non-alcoholic fatty liver disease but normal liver enzyme levels had multivariate adjusted hazard ratios for deaths from all causes of 0.92 (95% confidence interval 0.78 to 1.09), from cardiovascular disease of 0.86 (0.67 to 1.12), from cancer of 0.92 (0.67 to 1.27), and from liver disease of 0.64 (0.12 to 3.59). Compared with participants without steatosis, those with non-alcoholic fatty liver disease and increased liver enzyme levels had adjusted hazard ratios for deaths from all causes of 0.80 (0.52 to 1.22), from cardiovascular disease of 0.59 (0.29 to 1.20), from cancer of 0.53 (0.26 to 1.10), and from liver disease of 1.17 (0.15 to 8.93).
Non-alcoholic fatty liver disease was not associated with an increased risk of death from all causes, cardiovascular disease, cancer, or liver disease.
评估非酒精性脂肪性肝病与美国代表性人群全因和特定病因死亡率之间的关联。
前瞻性队列研究。
美国第三次国家健康和营养调查(NHANES III:1988-94 年),随访至 2006 年死亡。
11371 名年龄在 20-74 岁之间的成年人参加了第三次国家健康和营养调查,评估了肝脂肪变性。
全因死亡率、心血管疾病死亡率、癌症死亡率和肝病死亡率(随访 18 年)。
人群中存在和不存在肝酶升高的非酒精性脂肪性肝病的患病率分别为 3.1%和 16.4%。与无脂肪变性的参与者相比,非酒精性脂肪性肝病但肝酶水平正常的患者全因死亡的多变量调整危险比为 0.92(95%置信区间 0.78 至 1.09),心血管疾病死亡的危险比为 0.86(0.67 至 1.12),癌症死亡的危险比为 0.92(0.67 至 1.27),肝病死亡的危险比为 0.64(0.12 至 3.59)。与无脂肪变性的参与者相比,非酒精性脂肪性肝病且肝酶水平升高的患者全因死亡的调整危险比为 0.80(0.52 至 1.22),心血管疾病死亡的危险比为 0.59(0.29 至 1.20),癌症死亡的危险比为 0.53(0.26 至 1.10),肝病死亡的危险比为 1.17(0.15 至 8.93)。
非酒精性脂肪性肝病与全因死亡、心血管疾病、癌症或肝病的风险增加无关。